When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Colorectal cancer - Wikipedia

    en.wikipedia.org/wiki/Colorectal_cancer

    The use of radiotherapy in colon cancer is not routine due to the sensitivity of the bowels to radiation. [155] Radiation therapy's side effects (and occurrence rates) include acute (27%) and late (17%) dermatological toxicities, acute (14%) and late (27%) gastrointestinal toxicities, [154] and late pelvic radiation disease (1-10%), e.g ...

  3. Multimodal cancer therapy - Wikipedia

    en.wikipedia.org/wiki/Multimodal_cancer_therapy

    Multimodal cancer therapy, often referred to simply as multimodal therapy or multimodal cancer care, is an approach for treatment of cancer that combines radiation and chemotherapy [1] or other multiple therapeutic modalities.

  4. Chemoradiotherapy - Wikipedia

    en.wikipedia.org/wiki/Chemoradiotherapy

    Chemoradiotherapy (CRT, CRTx, CT-RT) is the combination of chemotherapy and radiotherapy to treat cancer. [1] Synonyms include radiochemotherapy (RCT, RCTx, RT-CT) and chemoradiation. It is a type of multimodal cancer therapy. Chemoradiation can be concurrent [2] (together) or sequential (one after the other). [3]

  5. What Is the Age Limit for Medicare Coverage of Cologuard?

    www.aol.com/lifestyle/age-limit-medicare...

    Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A ...

  6. Trifluridine/tipiracil - Wikipedia

    en.wikipedia.org/wiki/Trifluridine/tipiracil

    Trifluridine/tipiracil (FTD–TPI), sold under the brand name Lonsurf, is a fixed-dose combination medication that is used as a third- or fourth-line treatment of metastatic colorectal cancer or gastric cancer, after chemotherapy and targeted therapeutics have failed.

  7. U.S. FDA advisers back approval for Guardant's blood-based ...

    www.aol.com/news/u-fda-advisers-back-approval...

    Guardant's application for Shield was based on a study that showed the test detected 83% of colorectal cancers, while Exact's Cologuard had 92.3% sensitivity rate, according to the FDA's documents.

  8. Chemotherapy - Wikipedia

    en.wikipedia.org/wiki/Chemotherapy

    Nausea and vomiting are two of the most feared cancer treatment-related side-effects for people with cancer and their families. In 1983, Coates et al. found that people receiving chemotherapy ranked nausea and vomiting as the first and second most severe side-effects, respectively. [98]

  9. A blood test for colon cancer performed well in a study ...

    www.aol.com/news/blood-test-colon-cancer...

    A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.. The test looks for DNA fragments shed by tumor ...